Lupin Limited announced US FDA approval and launch of generic Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to AstraZeneca's Farxiga®.
The product launch expands Lupin's US portfolio in the cardiovascular and anti-diabetic therapy areas through its generic formulation.
Lupin is a global pharmaceutical company with products in over 100 markets and 15 manufacturing sites worldwide.
The disclosure was made pursuant to SEBI Listing Regulations through National Stock Exchange and BSE filing channels.